Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non-Small Cell Lung Cancer Tissues

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) are crucial for treating advanced non-small cell lung cancer (NSCLC) with EGFR-activating mutations.
• The EGFR C797S mutation is a known cause of acquired resistance to third-generation TKIs.
• A prevailing hypothesis suggests that pre-existing resistance mutations, even at low allele frequencies, can predict poor treatment response.

Purpose of the Study:

• To investigate the presence of the EGFR C797S mutation in previously untreated (TKI-naïve) NSCLC tumors.
• To determine if baseline screening for C797S is necessary prior to initiating EGFR TKI therapy.

Main Methods:

• Analysis of DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissues of 470 lung adenocarcinoma patients.
• Focus on 235 samples harboring activating EGFR mutations.
• Utilized a highly sensitive droplet digital PCR (ddPCR) assay for mutation screening.

Main Results:

• No EGFR C797S mutations were detected in any of the analyzed TKI-naïve NSCLC samples.
• The study found no evidence of baseline C797S occurrence in the patient cohort.
• This indicates C797S is not present before TKI treatment initiation.

Conclusions:

• The EGFR C797S mutation is absent in TKI-naïve NSCLC.
• Pre-treatment screening for the C797S mutation in lung adenocarcinoma patients is not clinically indicated.
• This finding simplifies treatment strategies and avoids unnecessary diagnostic procedures.